Guardant Health Presents New Data Showing Blood Test Accuracy in Detecting Colorectal Cancer in First-of-its Kind Prospective Study at Digestive Disease Week 2022
Yahoo! Finance
PALO ALTO, Calif., May 21, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced data showing its blood-based multimodal test achieved clinically significant thresholds of sensitivity and specificity in detecting colorectal cancer (CRC). These data were presented during an oral presentation at Digestive Disease Week 2022.
Continue Reading